Trulicity dulaglutide patent expiration biosimilar competition?

Short answer:
- There are no approved dulaglutide (Trulicity) biosimilars in the US or EU yet.
- Trulicity is still protected by a bundle of patents (on the molecule, formulations, devices, etc.) plus regulatory data exclusivity. That protection tends to delay biosimilar competition by several years beyond the launch in 2014.
- When biosimilars could appear depends on patent litigation/settlements and regulatory exclusivity, but most projections place potential first US/EU entries in the mid-to-late 2020s or early 2030s, not in the immediate near term.

Key points to know:
- Regulatory exclusivity: In the US, biologics generally have 12 years of data exclusivity; in the EU, data exclusivity is typically 10 years (with possible extensions for new indications, etc.). These protections delay biosimilar approvals even if patents expire.
- Patent landscape: Dulaglutide is covered by multiple patents (composition, manufacturing, formulation, devices, and method of use). Even after some patents expire, other patents and regulatory protections can keep competition at bay.
- Market status: No approved dulaglutide biosimilars have reached the market to date. Several companies have expressed development programs, but approvals have not materialized yet.

If you want, I can pull:
- The latest official patent expiry dates by jurisdiction (US, EU) and any known patent term extensions.
- The current FDA/EMA status on dulaglutide biosimilar development.
- Any recent patent litigations or settlements that could affect timing.

Tell me which region you care about (US or EU) and whether you want just a high-level view or up-to-date patent/legal details.